Copyright
©The Author(s) 2021.
World J Clin Cases. Jan 26, 2021; 9(3): 521-527
Published online Jan 26, 2021. doi: 10.12998/wjcc.v9.i3.521
Published online Jan 26, 2021. doi: 10.12998/wjcc.v9.i3.521
Ref. | Country | Sample size (EVL+APC/EVL) | Age (EVL+APC/EVL) (mean ± SD) | Gender (male/female) | Liver function classification (EVL+APC/EVL) | Pathogenic factors (EVL+APC/EVL) | Varicose vein types (EVL+APC/EVL) | Follow-up (EVL+APC/EVL) (mean ± SD) |
Nakamura et al[11]. 2001 | Japan | 30/30 | 63.7 ± 5.8/60.8 ± 7.1 | EVL+APC: 22/8; EVL: 21/9 | A: 9/7; B: 17/18; C: 4/5 | Virus: 25/26; Alcohol: 4/4; Others: 1/0 | F2: 19/17; F3: 11/13 | 18.5 ± 6.8/15.8 ± 7.7 |
Cipolletta et al[20]. 2002 | Italy | 16/14 | 62.8 ± 5.5/60.8 ± 6.2 | EVL+APC: 11/5; EVL: 10/4 | Not mentioned | Not mentioned | F2: 10/9; F3: 6/5 | 16.2 ± 5.8/16.5 ± 5.1 |
Harras et al[20]. 2010 | Egypt | 50/50 | 50.64 ± 10.43/48.96 ± 10.27 | Not mentioned | A: 10/14; B: 34/32; C: 6/4 | Virus: 50/50; Alcohol: 0/0; Others: 0/0 | F2: 3/0; F3: 47/50 | 16.3/17.4 |
Hamza I et al[21]. 2012 | Egypt | 30/30 | 50.23 ± 2.095/50 ± 2.104 | EVL+APC: 16/14; EVL: 18/12 | The two groups have the highest proportion of B grade, and there is no difference between the groups | Not mentioned | Post operative 3 mo: F0: 18/15; F1: 12/15; F2: 0/0 | Follow-up 3 mo and 6 mo |
Kamal et al[13]. 2017 | Egypt | 20/20 | 48.4/47.8 | Not mentioned | A:12/12; B: 6/6; C: 2/2 | Virus: 20/20; Alcohol: 0/0; Others: 0/0 | Not mentioned | Not mentioned |
Nakamura et al[11], 2001 | Cipolletta et al[19], 2002 | Harras et al[20], 2010 | Hamza I et al[21], 2012 | Kamal et al[13], 2017 | ||||||
Group | EVL+APC | EVL | EVL+APC | EVL | EVL+APC | EVL | EVL+APC | EVL | EVL+APC | EVL |
Sample size | 30 | 30 | 16 | 14 | 50 | 50 | 30 | 30 | 20 | 20 |
Varicose veins | No recurrence 74.2% | No recurrence 49.6% | Recurrence 0% | Recurrence 42.8% | Recurrence 4% | Recurrence 28% | Post operative 6 mo; F0: 16; F1: 14; F2: 0 | Post operative 6 mo; F0: 10; F1: 19; F2: 1 | Recurrence 21.1% | Recurrence 68.4% |
Recurrent bleeding | 3.3% | 6.7% | 0% | 7.2% | 2% | 8% | 0% | 0% | 0% | 10.5% |
Fever | 63.3% | 33.3% | 81.3% | 0% | 34% | 8% | 6.7% | 6.7% | 60% | 15% |
Difficulty swallowing | 30% | 26.7% | 50% | 0% | 36% | 12% | 3.3% | 3.3% | 35% | 30% |
Esophageal stenosis | 3.3% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Mortality | 0% | 0% | 0% | 0% | 8% | 12% | 0% | 0% | 5% | 5% |
Eradication course | 2.9 ± 0.6 | 2.5 ± 0.6 | Not mentioned | Not mentioned | 4.6 ± 0.7 | 3.7 ± 0.5 | 4.43 | 4.23 | Not mentioned | Not mentioned |
- Citation: Song Y, Feng Y, Sun LH, Zhang BJ, Yao HJ, Qiao JG, Zhang SF, Zhang P, Liu B. Role of argon plasma coagulation in treatment of esophageal varices. World J Clin Cases 2021; 9(3): 521-527
- URL: https://www.wjgnet.com/2307-8960/full/v9/i3/521.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i3.521